Panchratic Cancer - What's the Key Takeaway?

Thoro: We were able to identify a novel treatment resistant sub type of panchratic cancer, which we have annotated as a ner like progenitor sub type. This has very important clinical relevance in terms of patient outcomes, ah, and also has very unique spatial associations with other cell types. He says his lab is now working on three to four distinct follow up studies to this. Thoro: Our discovery here might actually be a central theme of treatment resistance across a lot of epithelial tumors, or carsonomas.